Information  X 
Enter a valid email address

Renalytix AI PLC (RENX)

  Print      Mail a friend

Tuesday 06 August, 2019

Renalytix AI PLC

Expansion of Chronic Kidney Disease Advisory Board

RNS Number : 9746H
Renalytix AI PLC
06 August 2019
 

6 August 2019
 

 

Renalytix AI plc

("RenalytixAI" or the "Company")

 

Expansion of Chronic Kidney Disease Advisory Board

 

Intended appointment of an additional Non-Executive Director

 

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence clinical in vitro diagnostics for kidney disease, announces the expansion of its core investigator group for lead product KidneyIntelX  for earlier identification of fast-progressing kidney disease in Type 2 diabetes.

 

The new advisory members are:

 

§ Jonathan Himmelfarb, MD, Professor Division of Nephrology University of Washington, Director Kidney Research Institute, Director, Center for Dialysis Innovation, Director Kidney Precision Medicine Project

https://nephrology.uw.edu/faculty/jonathan-himmelfarb-md 

 

§ Joseph Vassalotti, MD, FASN, Chief Medical Officer, National Kidney Foundation, Associate Clinical Professor of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai

https://www.kidney.org/about/board 

 

§ George Bakris, MD, Professor of Medicine, University of Chicago, Director, Comprehensive Hypertension Center, Member Board of Directors National Kidney Foundation

https://www.uchicagomedicine.org/find-a-physician/physician/george-bakris 

 

The Company intends to continue to build a diverse group of leading clinical and research advisors and investigators into its clinical trial, regulatory, reimbursement and commercial adoption programmes for KidneyIntelX. The Company believes expert opinion is critical to ensuring quality product development processes that adequately address unmet clinical need in chronic kidney disease and ensure optimal impact on improved patient outcomes and health economics.

 

The existing members of the RenalytixAI Chronic Kidney Disease Advisory Board are as follows:

 

·     Chirag Parikh (Chair), Director, Division of Nephrology, Ronald Peterson Professor of Medicine, Johns Hopkins School of Medicine

·     Sue Quaggin, MD, Director Feinberg Cardiovascular and Renal Research Institute, Chief of Nephrology and Hypertension, Department of Medicine Northwestern University

·     John Quackenbush, Ph.D., Professor of Computational Biology and Bioinformatics, Harvard T.H. Chan School of Public Health

·     Joe Bonventre, PhD., M.D., Samuel A. Levine Professor of Medicine, Harvard Medical School, Chief of Division of Renal Medicine and Chief of the Biomedical Engineering Division, Brigham and Women's Hospital

·     Barry Freedman, M.D., FACP, John H. Felts, III Professor of Medicine and Chief of the Section of Nephrology and Executive Director of the Kidney and Dialysis Service, Wake Forest Baptist Health

·     Judy Cho, M.D., Director and Associate Dean for Precision Medicine, Ward-Coleman Professor of Translational Genetics and Medicine Mount Sinai Health System

·     Girish Nadkarni, M.D., Assistant Professor of Medicine, Division of Nephrology; Clinical Director of the Charles Bronfman Institute for Personalized Medicine Mount Sinai Health System

·     Steven Coca, M.D., Associate Professor, Medicine, Nephrology; Associate Chair for Clinical and Translational Research for the Department of Internal Medicine, Mount Sinai Health System

 

The Company also provides as update in relation to its proposed appointment of a new Non-Executive Director, as announced in its Admission Document at the time of the Company's admission to trading on AIM. The Company intends to be in a position to announce the appointment of a new Non-Executive Director and healthcare industry veteran in advance of the Company's AGM at the end of September 2019.

                               

For further information, please contact:

 

Renalytix AI plc 

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR

 

 

Stifel (Nominated Adviser & Joint Broker)

Tel: 020 7710 7600

Alex Price / Jonathan Senior / Ben Maddison (Investment Banking)

Peter Lees (Corporate Broking)

 

 

 

N+1 Singer (Joint Broker)

Tel: 020 7496 3000

Aubrey Powell / James White / George Tzimas (Corporate Finance)
Tom Salvesen
/ Mia Gardner (Corporate Broking)

 

 

 

 

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

       

 

About Kidney Disease 

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

 

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBCGDIXUGBGCU

a d v e r t i s e m e n t